MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

Search

Quidel Corp

Fermé

33.23 -6.24

Résumé

Variation du prix de l'action

24h

Actuel

Min

32.93

Max

33.48

Chiffres clés

By Trading Economics

Employés

6,600

Recommandations

By TipRanks

Recommandations

Neutre

Prévisions sur 12 Mois

-25.1% downside

Dividendes

By Dow Jones

Prochains Résultats

11 févr. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

305M

1.9B

Ouverture précédente

39.47

Clôture précédente

33.23

Quidel Corp Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

16 janv. 2026, 23:29 UTC

Actions en Tendance

Stocks to Watch: Atossa Therapeutics, Union Pacific

16 janv. 2026, 22:48 UTC

Acquisitions, Fusions, Rachats

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- 2nd Update

16 janv. 2026, 22:43 UTC

Acquisitions, Fusions, Rachats

Union Pacific: Additional Information Requested to Be Provided to Surface Transportation Board

16 janv. 2026, 22:22 UTC

Acquisitions, Fusions, Rachats

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- Update

16 janv. 2026, 21:50 UTC

Market Talk
Acquisitions, Fusions, Rachats

Tech, Media & Telecom Roundup: Market Talk

16 janv. 2026, 21:50 UTC

Market Talk
Acquisitions, Fusions, Rachats

Auto & Transport Roundup: Market Talk

16 janv. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

16 janv. 2026, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

16 janv. 2026, 21:48 UTC

Market Talk
Acquisitions, Fusions, Rachats

Union Pacific, Norfolk Southern Market Share Ruled as Faulty -- Market Talk

16 janv. 2026, 21:41 UTC

Market Talk
Acquisitions, Fusions, Rachats

Union Pacific, Norfolk Southern Deal Rejection Leaves Questions -- Market Talk

16 janv. 2026, 21:38 UTC

Acquisitions, Fusions, Rachats

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- WSJ

16 janv. 2026, 21:30 UTC

Acquisitions, Fusions, Rachats

STB: Union Pacific, Norfolk Southern Application Doesn't Include 'Projected Market Shares' as Required

16 janv. 2026, 21:30 UTC

Acquisitions, Fusions, Rachats

STB: Union Pacific, Norfolk Southern Application Doesn't Include Certain Schedules, Documents Expressly Made Part of Merger Agreement

16 janv. 2026, 21:30 UTC

Acquisitions, Fusions, Rachats

STB: Union Pacific, Norfolk Southern Application Doesn't Contain Certain Information Required by Regulations

16 janv. 2026, 21:30 UTC

Acquisitions, Fusions, Rachats

STB: Application Rejected Without Prejudice to Union Pacific, Norfolk Southern Refiling Revised Application Remedying Deficiencies

16 janv. 2026, 21:30 UTC

Acquisitions, Fusions, Rachats

Surface Transportation Board: Union Pacific, Norfolk Southern Major Merger Application Filed Dec. 19 Incomplete

16 janv. 2026, 20:44 UTC

Résultats

5 Takeaways From This Season's Wealth Management Earnings -- Barrons.com

16 janv. 2026, 20:42 UTC

Market Talk

Oil Futures Post Fourth Straight Weekly Gain -- Market Talk

16 janv. 2026, 20:28 UTC

Market Talk

U.S. Natural Gas Slips Ahead of Long Weekend -- Market Talk

16 janv. 2026, 19:12 UTC

Market Talk
Acquisitions, Fusions, Rachats

Netflix Could Comment on Structure of Warner Bid During 4Q Results -- Market Talk

16 janv. 2026, 18:53 UTC

Market Talk

Global Crude Supply Enough to Absorb Any Iran Disruption -- Market Talk

16 janv. 2026, 18:41 UTC

Market Talk

Netflix's Ad Business Seen as Primary Revenue Driver in 2026 -- Market Talk

16 janv. 2026, 18:31 UTC

Market Talk

U.S. Oil Rig Count Rises By 1 to 410 -- Market Talk

16 janv. 2026, 17:20 UTC

Market Talk

Financial Services Roundup: Market Talk

16 janv. 2026, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

16 janv. 2026, 17:20 UTC

Market Talk

Health Care Roundup: Market Talk

16 janv. 2026, 17:03 UTC

Market Talk

Global Equities Roundup: Market Talk

16 janv. 2026, 17:03 UTC

Market Talk

All Eyes on Guidance for European Big Pharma Earnings Season -- Market Talk

16 janv. 2026, 16:32 UTC

Market Talk
Acquisitions, Fusions, Rachats

Sanofi Needs Dealmaking to Offset Pipeline Disappointments -- Market Talk

16 janv. 2026, 16:20 UTC

Market Talk

Global Equities Roundup: Market Talk

Comparaison

Variation de prix

Quidel Corp prévision

Objectif de Prix

By TipRanks

-25.1% baisse

Prévisions sur 12 Mois

Moyen 26.5 USD  -25.1%

Haut 31 USD

Bas 22 USD

Basé sur 5 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Neutre

5 ratings

1

Achat

3

Maintien

1

Vente

Éléments financiers

$

À Propos Quidel Corp

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.
help-icon Live chat